MET and cancer: Of these, c-Met exon 14 skipping mutations promote its oncogenic activity by suppressing c-Met receptor degradation.43,45,47 These mutations are rare in patients with primary tumors but common in advanced cancers with metastases, especially in lung adenocarcinoma, brain gliomas, and renal cell carcinoma (RCC).47,48